SST receptor quantitation - NODAGA-JR11 PET/CT in chest NET
Research type
Research Study
Full title
Quantification of somatostatin receptor subtype 2 expression in patients with bronchopulmonary and mediastinal neuroendocrine neoplasia using radiolabeled somatostatin receptor antagonists (NODAGA-JR11) PET/CT
IRAS ID
193785
Contact name
Jamshed Bomanji
Contact email
Sponsor organisation
UCL
Clinicaltrials.gov Identifier
Z6364106/2016/04/12, Data Protection Registration
Duration of Study in the UK
1 years, 5 months, 31 days
Research summary
Twenty to 25% of all lung malignancies are neuroendocrine tumours (NET), if the most aggressive, poorly differentiated, variants are included. Surgical resection remains the only curative treatment of localized disease, however there is currently a very limited number of systemic therapy established for advanced, unresectable disease. Somatostatin receptor subtype 2 (sst2) is an attractive molecular target because it is often overexpressed on the NET cell membrane and can be utilized for diagnostic or therapeutic purposes. Sst2 expression can be quantified with positron emission tomography (PET) in vivo. Currently there is no knowledge about the quantification of sst2 expression in the different types of NET originating from the bronchopulmonary system and mediastinum in vivo. The knowledge of sst2 expression in NET and their metastases is crucial for using somatostatin analogs targeting sst2 for imaging or therapy clinically. An accurate measurement of the sst-receptor density will help better identify patients susceptible to benefit from sst2 targeting therapy.
For our imaging study we plan to enrol at Royal Free and University College London Hospitals, 20 patients with broncho-pulmonary or mediastinal NET over an 18 month period. For detecting and quantifying sst2-expression in vivo, a PET combined with a computer tomography (PET/CT) will be acquired after administration of a radiolabelled sst-antagonist (NODAGA-JR11). Because uncertainty remains whether Ga-68 or Cu-64 NODAGA-JR11 is best, the first 10 patients will undergo both, Ga-68- and Cu-64-NODAGA-JR11 PET/CT. Results of the PET/CT will be correlated with ex vivo autoradiography used as a gold standard to quantify sst2 expression. The next 10 patients will be scanned with the best radiolabelled sst-antagonist and compared with the current standard imaging.
REC name
London - Surrey Borders Research Ethics Committee
REC reference
16/LO/1052
Date of REC Opinion
16 Sep 2016
REC opinion
Further Information Favourable Opinion